Altria Group(NYSE: MO) has been mainly known as a purveyor of cigarettes. That's a tough business as people become more health-conscious and regulators aren't fond of cigarette manufacturers. Yet Altria just got the green light from federal regulators to commercialize an apparently less harmful alternative to traditional cigarettes. There's certainly no guarantee that the cigarette-replacement product will gain traction among consumers, but at least there might be some benefit for smokers and for Altria's public image. Bullish news It's definitely bullish news for Altria that the company just received Food and Drug Administration (FDA) authorization for the marketing of four menthol-flavored e-vapor products. It now has the only FDA-authorized menthol e-vapor products on the market. The four products are all under Altria's NJOY brand: Ace Pod Menthol 2.4%, AceE Pod Menthol 5%, Daily Menthol 4.5%, and Daily Extra Menthol 6%. NJOY isn't a brand-new product line; its distribution spanned more than 80,000 stores in 2024's first quarter. Without delving too far into the science of e-vaping/e-cigarettes, they're basically a mechanism allowing the user to inhale a nicotine-infused aerosol. Johns Hopkins Medicine acknowledges that e-vaping is less harmful than smoking traditional cigarettes but also warns that it's not completely safe. As one might expect, Altria is emphasizing e-vaping's potential for reduced harm. This is a watershed moment for the vaping industry as a whole, and it's a pivot for the FDA, which previously rejected other menthol versions of vaping brands. One-third of traditional cigarettes sold in the U.S. are menthols, so Altria could have a significant revenue opportunity with the newly authorized menthol e-cigarettes. This might be a necessary shift for the company since cigarette smoking in the U.S. is on the decline. Investors should monitor NJOY sales and hope that Altria fares better with NJOY than it did with the failed Juul vaping brand, which it ended up divesting last year. A solid defensive pick Beyond the effects of the FDA's decision, Altria has something to offer value hunters, income collectors, and defensive-minded investors generally. During a time when stock indexes are often heavily weighted toward high-multiple technology giants, Altria stock looks like a comparative bargain. Currently, it has a trailing-12-month price-to-earnings (P/E) ratio of just 9.64, as measured under generally accepted accounting principles (GAAP). The company is also willing to return value to its shareholders. Its board authorized a $2.4 billion increase in the existing $1 billion share buyback program during this year's first quarter. Moreover, Altria pays a hefty 8.52% forward dividend yield. Altria has a good track record of increasing its dividend distributions, and it's hard to imagine that they are unsafe -- the company recently had $3.61 billion worth of cash and cash equivalents. On the other hand, it reported moderate year-over-year revenue and EPS declines in the first quarter. So, Altria isn't undergoing blockbuster growth at the moment. Still, at least federal regulators authorized some vaping products. With that in mind, investors can add a few Altria shares as a defensive holding in a legacy tobacco company that might actually be credited with reducing harm to the public's health, if you can believe it. Should you invest $1,000 in Altria Group right now? Before you buy stock in Altria Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Altria Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $786,046!* Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. TheStock Advisorservice has more than quadrupled the return of S&P 500 since 2002*. See the 10 stocks » *Stock Advisor returns as of July 2, 2024 David Moadel has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Altria Investors Just Got Some Bullish News was originally published by The Motley Fool
Altria Investors Just Got Some Bullish News
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...